Journal of Neurology

, Volume 259, Issue 10, pp 2182–2188 | Cite as

Comparison of clinical characteristics between familial and non-familial early onset Alzheimer’s disease

  • Aditi Joshi
  • John M. Ringman
  • Albert S. Lee
  • Kevin O. Juarez
  • Mario F. Mendez
Original Communication

Abstract

Although familial Alzheimer’s disease (FAD) is an early onset AD (EAD), most patients with EAD do not have a familial disorder. Recent guidelines recommend testing for genes causing FAD only in those EAD patients with two first-degree relatives. However, some patients with FAD may lack a known family history or other indications for suspecting FAD but might nonetheless be carriers of FAD mutations. The study was aimed to identify clinical features that distinguish FAD from non-familial EAD (NF-EAD). A retrospective review of a university-based cohort of 32 FAD patients with PSEN1-related AD and 81 with NF-EAD was conducted. The PSEN1 patients, compared to the NF-EAD patients, had an earlier age of disease onset (41.8 ± 5.2 vs. 55.9 ± 4.8 years) and, at initial assessment, a longer disease duration (5.1 ± 3.4 vs. 3.3 ± 2.6 years) and lower MMSE scores (10.74 ± 8.0 vs. 20.95 ± 5.8). Patients with NF-EAD were more likely to present with non-memory deficits, particularly visuospatial symptoms, than were FAD patients. When age, disease duration, and MMSE scores were controlled in a logistical regression model, FAD patients were more likely to have significant headaches, myoclonus, gait abnormality, and pseudobulbar affect than those with NF-EAD. In addition to a much younger age of onset, FAD patients with PSEN1 mutations differed from those with NF-EAD by a history of headaches and pseudobulbar affect, as well as myoclonus and gait abnormality on examination. These may represent differences in pathophysiology between FAD and NF-EAD and in some contexts such findings should lead to genetic counseling and appropriate recommendations for genetic testing for FAD.

Keywords

Dementia Early onset Alzheimer’s disease Familial Alzheimer’s disease PSEN1 gene 

References

  1. 1.
    Querfurth HW, LaFerla FM (2010) Alzheimer’s disease. N Engl J Med 362:329–344PubMedCrossRefGoogle Scholar
  2. 2.
    Mendez MF, Cummings JL (2003) Dementia: a clinical approach. Butterworth-Heinemann, PhiladelphiaGoogle Scholar
  3. 3.
    Balasa M, Gelpi E, Antonell A, Rey MJ, Sanchez-Valle R, Molinuevo JL, Llado A (2011) Clinical features and APOE genotype of pathologically proven early-onset Alzheimer disease. Neurology 76:1720–1725PubMedCrossRefGoogle Scholar
  4. 4.
    Galton CJ, Patterson K, Xuereb JH, Hodges JR (2000) Atypical and typical presentations of Alzheimer’s disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain 123(Pt 3):484–498PubMedCrossRefGoogle Scholar
  5. 5.
    Josephs KA, Whitwell JL, Duffy JR, Vanvoorst WA, Strand EA, Hu WT, Boeve BF, Graff-Radford NR, Parisi JE, Knopman DS, Dickson DW, Jack CR Jr, Petersen RC (2008) Progressive aphasia secondary to Alzheimer disease vs FTLD pathology. Neurology 70:25–34PubMedCrossRefGoogle Scholar
  6. 6.
    Larner AJ, Doran M (2006) Clinical phenotypic heterogeneity of Alzheimer’s disease associated with mutations of the presenilin-1 gene. J Neurol 253:139–158PubMedCrossRefGoogle Scholar
  7. 7.
    Goldman JS, Hahn SE, Catania JW, LaRusse-Eckert S, Butson MB, Rumbaugh M, Strecker MN, Roberts JS, Burke W, Mayeux R, Bird T (2011) Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med 13:597–605PubMedCrossRefGoogle Scholar
  8. 8.
    Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N et al (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med 2:864–870PubMedCrossRefGoogle Scholar
  9. 9.
    Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ (2010) Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science 330:1774PubMedCrossRefGoogle Scholar
  10. 10.
    Lemere CA, Lopera F, Kosik KS, Lendon CL, Ossa J, Saido TC, Yamaguchi H, Ruiz A, Martinez A, Madrigal L, Hincapie L, Arango JC, Anthony DC, Koo EH, Goate AM, Selkoe DJ (1996) The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. Nat Med 2:1146–1150PubMedCrossRefGoogle Scholar
  11. 11.
    Houlden H, Baker M, McGowan E, Lewis P, Hutton M, Crook R, Wood NW, Kumar-Singh S, Geddes J, Swash M, Scaravilli F, Holton JL, Lashley T, Tomita T, Hashimoto T, Verkkoniemi A, Kalimo H, Somer M, Paetau A, Martin JJ, Van Broeckhoven C, Golde T, Hardy J, Haltia M, Revesz T (2000) Variant Alzheimer’s disease with spastic paraparesis and cotton wool plaques is caused by PS-1 mutations that lead to exceptionally high amyloid-beta concentrations. Ann Neurol 48:806–808PubMedCrossRefGoogle Scholar
  12. 12.
    Lampe TH, Bird TD, Nochlin D, Nemens E, Risse SC, Sumi SM, Koerker R, Leaird B, Wier M, Raskind MA (1994) Phenotype of chromosome 14-linked familial Alzheimer’s disease in a large kindred. Ann Neurol 36:368–378PubMedCrossRefGoogle Scholar
  13. 13.
    Licht EA, McMurtray AM, Saul RE, Mendez MF (2007) Cognitive differences between early- and late-onset Alzheimer’s disease. Am J Alzheimers Dis Other Demen 22:218–222PubMedCrossRefGoogle Scholar
  14. 14.
    Mendez MF, Catanzaro P, Doss RC, ARguello R, Frey WH, 2nd (1994) Seizures in Alzheimer’s disease: clinicopathologic study. J Geriatr Psychiatry Neurol 7:230–233PubMedGoogle Scholar
  15. 15.
    Ringman JM (2005) What the study of persons at risk for familial Alzheimer’s disease can tell us about the earliest stages of the disorder: a review. J Geriatr Psychiatry Neurol 18:228–233PubMedCrossRefGoogle Scholar
  16. 16.
    Ringman JM, Romano JD, Medina LD, Rodriguez-Agudelo Y, Schaffer B, Varpetian A, Ortiz F, Fitten LJ, Cummings JL, Baloh RW (2008) Increased prevalence of significant recurrent headache in preclinical familial Alzheimer’s disease mutation carriers. Dement Geriatr Cogn Disord 25:380–384PubMedCrossRefGoogle Scholar
  17. 17.
    Lopera F, Ardilla A, Martinez A, Madrigal L, Arango-Viana JC, Lemere CA, Arango-Lasprilla JC, Hincapie L, Arcos-Burgos M, Ossa JE, Behrens IM, Norton J, Lendon C, Goate AM, Ruiz-Linares A, Rosselli M, Kosik KS (1997) Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA 277:793–799PubMedCrossRefGoogle Scholar
  18. 18.
    Murrell J, Ghetti B, Cochran E, Macias-Islas MA, Medina L, Varpetian A, Cummings JL, Mendez MF, Kawas C, Chui H, Ringman JM (2006) The A431E mutation in PSEN1 causing Familial Alzheimer’s disease originating in Jalisco State, Mexico: an additional fifteen families. Neurogenetics 7:277–279PubMedCrossRefGoogle Scholar
  19. 19.
    Athan ES, Williamson J, Ciappa A, Santana V, Romas SN, Lee JH, Rondon H, Lantigua RA, Medrano M, Torres M, Arawaka S, Rogaeva E, Song YQ, Sato C, Kawarai T, Fafel KC, Boss MA, Seltzer WK, Stern Y, St George-Hyslop P, Tycko B, Mayeux R (2001) A founder mutation in presenilin 1 causing early-onset Alzheimer disease in unrelated Caribbean Hispanic families. JAMA 286:2257–2263PubMedCrossRefGoogle Scholar
  20. 20.
    Janssen JC, Beck JA, Campbell TA, Dickinson A, Fox NC, Harvey RJ, Houlden H, Rossor MN, Collinge J (2003) Early onset familial Alzheimer’s disease: mutation frequency in 31 families. Neurology 60:235–239PubMedCrossRefGoogle Scholar
  21. 21.
    Morelli L, Prat MI, Levy E, Mangone CA, Castano EM (1998) Presenilin 1 Met146Leu variant due to an A → T transversion in an early-onset familial Alzheimer’s disease pedigree from Argentina. Clin Genet 53:469–473PubMedCrossRefGoogle Scholar
  22. 22.
    Ringman JM, Gylys KH, Medina LD, Fox M, Kepe V, Flores DL, Apostolova LG, Barrio JR, Small G, Silverman DH, Siu E, Cederbaum S, Hecimovic S, Malnar M, Chakraverty S, Goate AM, Bird TD, Leverenz JB (2011) Biochemical, neuropathological, and neuroimaging characteristics of early-onset Alzheimer’s disease due to a novel PSEN1 mutation. Neurosci Lett 487:287–292PubMedCrossRefGoogle Scholar
  23. 23.
    Gomez-Isla T, Wasco W, Pettingell WP, Gurubhagavatula S, Schmidt SD, Jondro PD, McNamara M, Rodes LA, DiBlasi T, Growdon WB, Seubert P, Schenk D, Growdon JH, Hyman BT, Tanzi RE (1997) A novel presenilin-1 mutation: increased beta-amyloid and neurofibrillary changes. Ann Neurol 41:809–813PubMedCrossRefGoogle Scholar
  24. 24.
    Edwards-Lee T, Wen J, Bell J, Hardy J, Chung J, Momeni P (2006) A presenilin-1 mutation (T245P) in transmembrane domain 6 causes early onset Alzheimer’s disease. Neurosci Lett 398:251–252PubMedCrossRefGoogle Scholar
  25. 25.
    Koedam EL, Lauffer V, van der Vlies AE, van der Flier WM, Scheltens P, Pijnenburg YA (2010) Early-versus late-onset Alzheimer’s disease: more than age alone. J Alzheimers Dis 19:1401–1408PubMedGoogle Scholar
  26. 26.
    Borroni B, Pilotto A, Bonvicini C, Archetti S, Alberici A, Lupi A, Gennarelli M, Padovani A (2011) Atypical presentation of a novel Presenilin 1 R377 W mutation: sporadic, late-onset Alzheimer disease with epilepsy and frontotemporal atrophy. Neurol Sci Issn: 1590-1874:1-4Google Scholar
  27. 27.
    Amatniek JC, Hauser WA, DelCastillo-Castaneda C, Jacobs DM, Marder K, Bell K, Albert M, Brandt J, Stern Y (2006) Incidence and predictors of seizures in patients with Alzheimer’s disease. Epilepsia 47:867–872PubMedCrossRefGoogle Scholar
  28. 28.
    Friedman D, Honig LS, Scarmeas N (2011) Seizures and epilepsy in Alzheimer’s disease. CNS Neurosci Ther. doi:10.1111/j.1755-5949.2011.00251.x PubMedGoogle Scholar
  29. 29.
    Mendez MF, Ghajarania M, Perryman KM (2002) Posterior cortical atrophy: clinical characteristics and differences compared to Alzheimer’s disease. Dement Geriatr Cogn Disord 14:33–40PubMedCrossRefGoogle Scholar
  30. 30.
    Tsai PH, Teng E, Liu C, Mendez MF (2011) Posterior cortical atrophy: evidence for discrete syndromes of early-onset Alzheimer’s disease. Am J Alzheimers Dis Other Demen 26:413–418PubMedCrossRefGoogle Scholar
  31. 31.
    Stopford CL, Snowden JS, Thompson JC, Neary D (2008) Variability in cognitive presentation of Alzheimer’s disease. Cortex 44:185–195PubMedCrossRefGoogle Scholar
  32. 32.
    Suribhatla S, Baillon S, Dennis M, Marudkar M, Muhammad S, Munro D, Spreadbury C, Lindesay J (2004) Neuropsychological performance in early and late onset Alzheimer’s disease: comparisons in a memory clinic population. Int J Geriatr Psychiatry 19:1140–1147PubMedCrossRefGoogle Scholar
  33. 33.
    Padovani A, Gilberti N, Borroni B (2011) The usefulness of biological and neuroimaging markers for the diagnosis of early-onset Alzheimer’s disease. Int J Alzheimers Dis 2011:296374PubMedGoogle Scholar
  34. 34.
    McMurtray AM, Licht E, Yeo T, Krisztal E, Saul RE, Mendez MF (2008) Positron emission tomography facilitates diagnosis of early-onset Alzheimer’s disease. Eur Neurol 59:31–37PubMedCrossRefGoogle Scholar
  35. 35.
    Fox NC, Warrington EK, Stevens JM, Rossor MN (1996) Atrophy of the hippocampal formation in early familial Alzheimer’s disease. A longitudinal MRI study of at-risk members of a family with an amyloid precursor protein 717Val-Gly mutation. Ann N Y Acad Sci 777:226–232PubMedCrossRefGoogle Scholar
  36. 36.
    Pedrosa R, Teixeira-Sousa V, Fonseca S, Bastos-Leite AJ (2010) Early-onset Alzheimer disease: the contribution of neuroimaging for the diagnosis. Psychiatry Res 182:287–288PubMedCrossRefGoogle Scholar
  37. 37.
    Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, Bi W, Hoge JA, Cohen AD, Ikonomovic MD, Saxton JA, Snitz BE, Pollen DA, Moonis M, Lippa CF, Swearer JM, Johnson KA, Rentz DM, Fischman AJ, Aizenstein HJ, DeKosky ST (2007) Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 27:6174–6184PubMedCrossRefGoogle Scholar
  38. 38.
    Knight WD, Okello AA, Ryan NS, Turkheimer FE, Rodriguez Martinez de Llano S, Edison P, Douglas J, Fox NC, Brooks DJ, Rossor MN (2011) Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. Brain 134:293–300PubMedCrossRefGoogle Scholar
  39. 39.
    Portelius E, Andreasson U, Ringman JM, Buerger K, Daborg J, Buchhave P, Hansson O, Harmsen A, Gustavsson MK, Hanse E, Galasko D, Hampel H, Blennow K, Zetterberg H (2010) Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer’s disease. Mol Neurodegener 5:2PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Aditi Joshi
    • 1
    • 2
  • John M. Ringman
    • 1
    • 3
    • 4
  • Albert S. Lee
    • 5
  • Kevin O. Juarez
    • 2
  • Mario F. Mendez
    • 1
    • 2
    • 3
    • 4
    • 5
  1. 1.Department of Neurology, David Geffen School of MedicineUniversity of California at Los AngelesLos AngelesUSA
  2. 2.Section of Neurology, Neurobehavior Unit (691/116AF)V.A. Greater Los Angeles Healthcare CenterLos AngelesUSA
  3. 3.Psychiatry and Biobehavioral Sciences, David Geffen School of MedicineUniversity of California at Los AngelesLos AngelesUSA
  4. 4.Mary S. Easton Center for Alzheimer’s Disease ResearchUniversity of California at Los AngelesLos AngelesUSA
  5. 5.Western University of Health SciencesPomonaCalifornia

Personalised recommendations